|
| 34017063 | Artificial intelligence for advance requesting of immunohistochemistry in diagnostically uncertain prostate biopsies. | Mod Pathol | 2021 |
| 34017063 | Artificial intelligence for advance requesting of immunohistochemistry in diagnostically uncertain prostate biopsies. | Mod Pathol | 2021 |
| 34676045 | ATR inhibition reverses the resistance of homologous recombination deficient MGMT<sup>low</sup>/MMR<sup>proficient</sup> cancer cells to temozolomide. | Oncotarget | 2021 |
| 35008201 | Combination of Wnt/β-Catenin Targets S100A4 and DKK1 Improves Prognosis of Human Colorectal Cancer. | Cancers (Basel) | 2021 |
| 35008201 | Combination of Wnt/β-Catenin Targets S100A4 and DKK1 Improves Prognosis of Human Colorectal Cancer. | Cancers (Basel) | 2021 |
| 34676045 | ATR inhibition reverses the resistance of homologous recombination deficient MGMT<sup>low</sup>/MMR<sup>proficient</sup> cancer cells to temozolomide. | Oncotarget | 2021 |
| 31367787 | Identification of pharmacodynamic biomarkers and common molecular mechanisms of response to genotoxic agents in cancer cell lines. | Cancer Chemother Pharmacol | 2019 |
| 31367787 | Identification of pharmacodynamic biomarkers and common molecular mechanisms of response to genotoxic agents in cancer cell lines. | Cancer Chemother Pharmacol | 2019 |
| 30355619 | The NCI Transcriptional Pharmacodynamics Workbench: A Tool to Examine Dynamic Expression Profiling of Therapeutic Response in the NCI-60 Cell Line Panel. | Cancer Res | 2018 |
| 30355619 | The NCI Transcriptional Pharmacodynamics Workbench: A Tool to Examine Dynamic Expression Profiling of Therapeutic Response in the NCI-60 Cell Line Panel. | Cancer Res | 2018 |
| 28709950 | Characterization of potent and selective iodonium-class inhibitors of NADPH oxidases. | Biochem Pharmacol | 2017 |
| 28709950 | Characterization of potent and selective iodonium-class inhibitors of NADPH oxidases. | Biochem Pharmacol | 2017 |
| 29276373 | Longitudinal Transcriptional Response of Glycosylation-Related Genes, Regulators, and Targets in Cancer Cell Lines Treated With 11 Antitumor Agents. | Cancer Inform | 2017 |
| 29276373 | Longitudinal Transcriptional Response of Glycosylation-Related Genes, Regulators, and Targets in Cancer Cell Lines Treated With 11 Antitumor Agents. | Cancer Inform | 2017 |
| 26683772 | Bromodomain and hedgehog pathway targets in small cell lung cancer. | Cancer Lett | 2016 |
| 27347216 | Concerted changes in transcriptional regulation of genes involved in DNA methylation, demethylation, and folate-mediated one-carbon metabolism pathways in the NCI-60 cancer cell line panel in response to cancer drug treatment. | Clin Epigenetics | 2016 |
| 27247353 | Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression. | J Natl Cancer Inst | 2016 |
| 26683772 | Bromodomain and hedgehog pathway targets in small cell lung cancer. | Cancer Lett | 2016 |
| 27347216 | Concerted changes in transcriptional regulation of genes involved in DNA methylation, demethylation, and folate-mediated one-carbon metabolism pathways in the NCI-60 cancer cell line panel in response to cancer drug treatment. | Clin Epigenetics | 2016 |
| 27247353 | Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression. | J Natl Cancer Inst | 2016 |
| 26474663 | Antitumour benzothiazoles. Part 32: DNA adducts and double strand breaks correlate with activity; synthesis of 5F203 hydrogels for local delivery. | Bioorg Med Chem | 2015 |
| 26474663 | Antitumour benzothiazoles. Part 32: DNA adducts and double strand breaks correlate with activity; synthesis of 5F203 hydrogels for local delivery. | Bioorg Med Chem | 2015 |
| 26351324 | Sarcoma Cell Line Screen of Oncology Drugs and Investigational Agents Identifies Patterns Associated with Gene and microRNA Expression. | Mol Cancer Ther | 2015 |
| 26351324 | Sarcoma Cell Line Screen of Oncology Drugs and Investigational Agents Identifies Patterns Associated with Gene and microRNA Expression. | Mol Cancer Ther | 2015 |
| 24553119 | Bioenergetic properties of human sarcoma cells help define sensitivity to metabolic inhibitors. | Cell Cycle | 2014 |
| 24553119 | Bioenergetic properties of human sarcoma cells help define sensitivity to metabolic inhibitors. | Cell Cycle | 2014 |
| 23437320 | A small molecule (pluripotin) as a tool for studying cancer stem cell biology: proof of concept. | PLoS One | 2013 |
| 23437320 | A small molecule (pluripotin) as a tool for studying cancer stem cell biology: proof of concept. | PLoS One | 2013 |
| 23630200 | Cediranib for metastatic alveolar soft part sarcoma. | J Clin Oncol | 2013 |
| 23630200 | Cediranib for metastatic alveolar soft part sarcoma. | J Clin Oncol | 2013 |
| 21765476 | CHEK2 genomic and proteomic analyses reveal genetic inactivation or endogenous activation across the 60 cell lines of the US National Cancer Institute. | Oncogene | 2012 |
| 22870217 | Identification of CBX3 and ABCA5 as putative biomarkers for tumor stem cells in osteosarcoma. | PLoS One | 2012 |
| 21765476 | CHEK2 genomic and proteomic analyses reveal genetic inactivation or endogenous activation across the 60 cell lines of the US National Cancer Institute. | Oncogene | 2012 |
| 22870217 | Identification of CBX3 and ABCA5 as putative biomarkers for tumor stem cells in osteosarcoma. | PLoS One | 2012 |
| 20618971 | Adaphostin toxicity in a sensitive non-small cell lung cancer model is mediated through Nrf2 signaling and heme oxygenase 1. | J Exp Clin Cancer Res | 2010 |
| 20618971 | Adaphostin toxicity in a sensitive non-small cell lung cancer model is mediated through Nrf2 signaling and heme oxygenase 1. | J Exp Clin Cancer Res | 2010 |
| 20472436 | Development of antiproliferative phenylmaleimides that activate the unfolded protein response. | Bioorg Med Chem | 2010 |
| 20472436 | Development of antiproliferative phenylmaleimides that activate the unfolded protein response. | Bioorg Med Chem | 2010 |
| 18641988 | Growth inhibition of hepatocellular carcinoma cells in vitro and in vivo by the 8-methoxy analog of WMC79. | Cancer Chemother Pharmacol | 2009 |
| 19364967 | Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. | J Clin Oncol | 2009 |
| 19741151 | Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide]. | J Pharmacol Exp Ther | 2009 |
| 19606018 | Gene expression-signature of belinostat in cell lines is specific for histone deacetylase inhibitor treatment, with a corresponding signature in xenografts. | Anticancer Drugs | 2009 |
| 18641988 | Growth inhibition of hepatocellular carcinoma cells in vitro and in vivo by the 8-methoxy analog of WMC79. | Cancer Chemother Pharmacol | 2009 |
| 19606018 | Gene expression-signature of belinostat in cell lines is specific for histone deacetylase inhibitor treatment, with a corresponding signature in xenografts. | Anticancer Drugs | 2009 |
| 19741151 | Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide]. | J Pharmacol Exp Ther | 2009 |
| 19364967 | Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. | J Clin Oncol | 2009 |
| 16332985 | Differential gene expression as a potential classifier of 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole-sensitive and -insensitive cell lines. | Mol Pharmacol | 2006 |
| 16332985 | Differential gene expression as a potential classifier of 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole-sensitive and -insensitive cell lines. | Mol Pharmacol | 2006 |
| 16714403 | Drug-induced expression of nonsteroidal anti-inflammatory drug-activated gene/macrophage inhibitory cytokine-1/prostate-derived factor, a putative tumor suppressor, inhibits tumor growth. | J Pharmacol Exp Ther | 2006 |
| 16714403 | Drug-induced expression of nonsteroidal anti-inflammatory drug-activated gene/macrophage inhibitory cytokine-1/prostate-derived factor, a putative tumor suppressor, inhibits tumor growth. | J Pharmacol Exp Ther | 2006 |